# Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections

> **NCT02002377** · PHASE4 · TERMINATED · sponsor: **Unity Health Toronto** · enrollment: 23 (actual)

## Conditions studied

- Age Related Macular Degeneration

## Interventions

- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT02002377
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04-17
- **Primary completion:** 2017-02-21
- **Final completion:** 2017-02-21
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Inadequate enrollment due to investigational product becoming newly available on the Canadian market soon after study start
- **Last updated:** 2018-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02002377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02002377, "Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02002377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*